Document Detail

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
MedLine Citation:
PMID:  7560608     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation. BACKGROUND: Atrial fibrillation is the most common arrhythmia. Pharmacologic therapy has been advocated for both immediate restoration of sinus rhythm and prevention of recurrent atrial fibrillation. Quinidine is the therapeutic mainstay for both purposes, but its safety has recently been questioned. Although sotalol has been used successfully to maintain sinus rhythm after direct current cardioversion, its efficacy in pharmacologically reverting atrial fibrillation has not been examined. METHODS: Fifty consecutive patients with persistent atrial fibrillation were randomized to receive quinidine or sotalol for up to 7 days to restore sinus rhythm. Patients were followed up for 6 months. RESULTS: Quinidine was more effective than sotalol in terminating atrial fibrillation (60% vs. 20%, p = 0.009). When nonresponders to drug therapy underwent subsequent direct current cardioversion, total conversion rates in the quinidine and sotalol groups were comparable (88% vs. 68%, p = 0.17), as was the efficacy of the two drugs in preventing recurrent atrial fibrillation. Side effects necessitating drug discontinuation were more often observed with quinidine. No patient receiving sotalol but four patients receiving quinidine had drug-associated arrhythmia (torsade de pointes in three patients, sustained ventricular tachycardia in one patient). Precordial QT dispersion determined on the surface electrocardiogram (ECG) increased with quinidine (mean +/- SD 34 +/- 9 vs. 44 +/- 16 ms, p = 0.02), indicating enhanced inhomogeneity in ventricular repolarization. There was no change in QT dispersion in patients receiving sotalol (36 +/- 18 vs. 40 +/- 17 ms, p = 0.44). CONCLUSIONS: Quinidine is more effective than sotalol in terminating atrial fibrillation but is associated with more side effects. The proarrhythmic risk may be related to quinidine's propensity to increase disparity in ventricular repolarization. This risk warrants careful ECG monitoring during the 1st 4 to 7 days of therapy. Because most proarrhythmic effects occurred shortly after restoration of sinus rhythm, observation should continue > or = 2 to 3 days after sinus rhythm is reestablished.
S H Hohnloser; A van de Loo; F Baedeker
Related Documents :
22322568 - Longitudinal heterogeneity of coronary artery distensibility in plaques related to acut...
16839828 - The influence of swelling and matrix degradation on the microstructural integrity of te...
19898288 - Potential application of late sodium current blockade in the treatment of heart failure...
7406578 - Peripheral arterial emboli and factors in their recurrence rate.
4026488 - Long-term follow-up after recovery from acute myocardial infarction. observations on su...
6210808 - Modification of myocardial ischemia in normal and hypertrophied hearts utilizing diasto...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  26     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1995-10-24     Completed Date:  1995-10-24     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  852-8     Citation Subset:  AIM; IM    
Department of Cardiology, University Hospital, Freiburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / adverse effects*,  therapeutic use*
Arrhythmias, Cardiac / chemically induced*
Atrial Fibrillation / diagnosis,  drug therapy*,  epidemiology
Drug Administration Schedule
Electrocardiography, Ambulatory
Follow-Up Studies
Middle Aged
Prospective Studies
Quinidine / adverse effects*,  therapeutic use*
Risk Factors
Sotalol / adverse effects*,  therapeutic use*
Time Factors
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 3930-20-9/Sotalol; 56-54-2/Quinidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiofrequency catheter ablation for management of symptomatic ventricular ectopic activity.
Next Document:  Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus.